ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells

Warning

This publication doesn't include Faculty of Medicine. It includes Faculty of Science. Official publication website can be found on muni.cz.

Authors

KOTAŠKOVÁ Jana PAVLOVÁ Šárka GREIF Igor STEHLÍKOVÁ Olga PLEVOVÁ Karla JANOVSKÁ Pavlína BRYCHTOVÁ Yvona DOUBEK Michael POSPÍŠILOVÁ Šárka BRYJA Vítězslav

Year of publication 2016
Type Article in Periodical
Magazine / Source British Journal of Haematology
MU Faculty or unit

Faculty of Science

Citation
Web http://onlinelibrary.wiley.com/doi/10.1111/bjh.13848/epdf
Doi http://dx.doi.org/10.1111/bjh.13848
Field Oncology and hematology
Keywords ROR1; cell isolation; chronic lymphocytic leukaemia; complete remission
Attached files
Description Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among adults in the Western world. This lymphoproliferative disorder is defined by the presence of at least 5 9 106 clonal lymphocytes/ml peripheral blood (Hallek,2015). The biggest clinical challenge is the fact that CLL eradication by any available therapy, apart from allogeneic stem cell transplantation, fails to cure the disease, inducing only temporary disease remission, i.e., when the disease does not manifest clinically but CLL cells still persist in the body. During this phase a population of CLL cells often slowly re-expands to trigger CLL relapse. The relapse is often based on the poorly understood but clinically important process of therapy-driven selection of more aggressive CLL subclones (Malcikova et al, 2015).
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info